Biontech aktie

biontech aktie

What is the price target for biontech stock?

Their forecasts range from $146.00 to $433.00. On average, they expect BioNTechs stock price to reach $292.15 in the next year. This suggests a possible upside of 35.3% from the stocks current price. View analysts price targets for BioNTech or view top-rated stocks among Wall Street analysts. Who are BioNTechs key executives?

What is the upside for biontech (BNT) stock?

On average, they expect BioNTechs stock price to reach $292.15 in the next year. This suggests a possible upside of 35.3% from the stocks current price. View analysts price targets for BioNTech or view top-rated stocks among Wall Street analysts.

What is biontech se?

BioNTech SE provides biotechnological solutions. The Company develops various types of treatments for cancer patients tumors. BioNTech serves customers worldwide.

Who are biontechs major shareholders?

BioNTech trades on the NASDAQ under the ticker symbol BNTX. Who are BioNTechs major shareholders? BioNTechs stock is owned by a number of institutional and retail investors. Top institutional investors include Magnolia Capital Management Ltd. (0.00%), Carroll Financial Associates Inc. (0.00%) and Harbor Investment Advisory LLC (0.00%).

What are analystsprice targets for biontechs stock?

13 analysts have issued twelve-month price targets for BioNTechs shares. Their forecasts range from $146.00 to $433.00. On average, they expect BioNTechs stock price to reach $292.15 in the next year.

What will biontech (bntx) stock price be in 2021?

BioNTech (BNTX) stock Forecast for 2021, 2022, 2023, 2024, 2025. What analysts predict:: $315.13 This figure corresponds to the average price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today. For BioNTech stocks, the 200-day moving average is the support level today.

What is biontechs price expectations for the next year?

Their forecasts range from $104.00 to $240.00. On average, they expect BioNTechs stock price to reach $159.70 in the next year. This suggests that the stock has a possible downside of 24.8%.

How does biontech stock compare to other medical stocks?

MarketBeat users like BioNTech stock less than the stock of other Medical companies. 52.76% of MarketBeat users gave BioNTech an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users. Is BioNTech being upgraded by Wall Street analysts?

The BNTX (BNTX ) future stock price will be 2642.140 USD . Will BNTX stock price crash? According to our analysis, this will not happen. Will BioNTech SE - ADR stock price hit 1 000 USD price in a year?

Does biontech have an upside of 15%?

According to analysts, BioNTechs stock has a predicted upside of 15.30% based on their 12-month price targets. What analysts cover BioNTech?

Should you hold biontech (bntx) stock?

The average twelve-month price target for BioNTech is $288.43 with a high price target of $433.00 and a low price target of $146.00. Learn more Do Wall Street analysts like BioNTech more than its competitors? Analysts like BioNTech stock less than the stock of other Medical companies.

What does biontech se stand for?

/ 49.9878; 8.2713 BioNTech SE ( / baɪˈɒntɛk / bye-ON-tek or / biːˈɒntɛk / bee-ON-tek; short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.

Who is biontech US?

BioNTech US originated as Neon Therapeutics, which was acquired by BioNTech SE in 2020 to combine neoantigen expertise in the field of cancer medicine and immunology by leveraging the highly complementary capabilities and resources of the two companies.

Why are biontech shares surging today?

Shares of vaccine maker BioNTech (NASDAQ: BNTX) were surging today, up 6.9%. The German mRNA vaccine producer, which partners with Pfizer (NYSE: PFE) on the COVID-19 mRNA vaccine, was surging after some good news on trials for its new booster late last week.

Which country has secured 90 million doses from Pfizer/biontech?

Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva. Reuters. London. Retrieved 2 August 2020. ^ SE, BioNTech (5 August 2020). Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate. GlobeNewswire News Room. Retrieved 3 February 2021. ^ Fortuna, Gerardo (8 January 2021).

Postagens relacionadas: